๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
NCT06007729Head and Neck Squamous Cell Carcinoma
Hansoh BioMedical R&D Company
Phase 2
170
Hefei, Beijing, Fuzhou, Guangzhou, Zhuhai, Nanning, Harbin, Zhengzhou
2023-12-18
Recruiting
HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
NCT06014190Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
Hansoh BioMedical R&D Company
Phase 2
460
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Haikou, Shijiazhuang
2023-12-18
Recruiting
Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease
NCT06359795Thyroid Eye Disease
Peking University Third Hospital
Not applicable
50
Beijing
2023-12-15
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) โ‰ฅ 50% (MK-2870-007)
NCT06170788Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Phase 3
614
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Zhanjiang, Shijiazhuang, Harbin
2023-12-15
Recruiting
A Study of YL202 in Selected Patients With Advanced Solid Tumors
NCT06107686NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shantou, Guilin
2023-12-15
Recruiting
Simplification of Oral Sodium Loading Test in the Diagnosis of Primary Aldosteronism: 2-day Replacing 3-day Method
NCT06750172Primary Aldosteronism
Peking Union Medical College Hospital
Observational
33
Beijing
2023-12-15
Recruiting
ALI/ARDS Clinical Sub-phenotyping Study
NCT06123962Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)
China-Japan Friendship Hospital
Observational
1,500
Beijing
2023-12-14
Recruiting
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca
Phase 3
1,145
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dongwan, Fuzhou
2023-12-14
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
Sanofi
Phase 3
1,655
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Fuzhou, Guangzhou
2023-12-13
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Merck Sharp & Dohme LLC
Phase 3
1,200
Hefei, Beijing, Chongqing, Guangzhou, Liuzhou, Nanning, Guiyang, Haikou
2023-12-13
Active, closed
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
NCT05991323Prurigo Nodularis
Sanofi
Observational
100
Guangzhou, Xi'an, Jinan, Hangzhou, Wenzhou, Beijing, Shanghai, Shenzhen
2023-12-12
Active, closed
Transcranial Near-infrared Light Therapy for Mild-Moderate Alzheimer's Disease (NIR4AD)
NCT06160908Alzheimer Disease
Xuanwu Hospital, Beijing
Not applicable
38
Beijing
2023-12-12
Recruiting
A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs
NCT07057622NETS Ga68 Lu177
HTA Co., Ltd.
Phase 3
184
Beijing
2023-12-12
Active, closed
A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA)
NCT06276998Rheumatoid Arthritis
Lynk Pharmaceuticals Co., Ltd
Phase 3
430
Beijing
2023-12-12
Recruiting
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05995353Crohn's Disease
AbbVie
Phase 3
110
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2023-12-11
Recruiting
Optimal Evaluation to Reduce Cardiovascular Imaging Testing
NCT05640752Chronic Coronary Syndrome
Tianjin Chest Hospital
Not applicable
800
Beijing, Lanfang, Tianjin
2023-12-11
Active, closed
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche
Phase 3
1,050
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2023-12-11
Recruiting
Chinese Occupational Population Cohort of Lifestyle and Physical Fitness (LiFitChina)
NCT06275009Lifestyle, Physical Fitness, Cardiovascular Diseases
China National Center for Cardiovascular Diseases
Observational
18,512
Beijing
2023-12-11
Recruiting
Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage
NCT05939167AIDS
Cell Energy Life Sciences Group Co. LTD
Phase 1/2
150
Beijing, Shenzhen, Shijiazhuang
2023-12-10
Recruiting
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
NCT06157827Advanced Neuroendocrine Carcinoma
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
178
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Luoyang
2023-12-08
Recruiting
COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research
NCT06168032COVID-19 Recurrent, Lung Cancer, Vaccination, Antibody
Peking Union Medical College Hospital
Not applicable
1,224
Beijing
2023-12-08
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
Merck Sharp & Dohme LLC
Phase 3
710
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shantou, Zhanjiang, Nanning
2023-12-06
Recruiting
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
NCT06106945Multiple Myeloma
AstraZeneca
Phase 1/2
226
Beijing, Changsha, Guangzhou, Shenyang
2023-12-05
Recruiting
Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis
NCT06167174Lupus Nephritis
Chinese SLE Treatment And Research Group
Observational
100
Beijing
2023-12-05
Recruiting
Evaluation of Membrane Lung Function in High-altitude Regions
NCT06152744Extracorporeal Membrane Oxygenation, Membrane Lung Function, High Altitude
Beijing Chao Yang Hospital
Observational
40
Beijing
2023-12-05
By invitation
The Differences in the Psychological States of Patients with Different Chronic Hip Pain
NCT06611722Psychological Disorders, Hip Pain Chronic
ChunBao Li
Observational
70
Beijing
2023-12-05
Active, closed
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06109779Biliary Tract Cancer
AstraZeneca
Phase 3
760
Beijing, Changchun, Changsha, Chengdu, Deyang, Fuzhou, Guangzhou, Guiyang
2023-12-04
Recruiting
Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia
NCT05998759Connective Tissue Diseases, Thrombocytopenia
Beijing Hospital
Phase 2
296
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Hohhot, Shenyang
2023-12-02
Recruiting
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
NCT06079983Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3
400
Guangzhou, Shanghai, Anyang, Baoding, Beijing, Changchun, Changde, Changsha
2023-12-01
By invitation
Clinical Study of Antiviral Therapy Combined With Novel Immunotherapy for CHB in Adults
NCT06777173Chronic Hepatitis b, Immunotherapy
Beijing Ditan Hospital
Not applicable
180
Beijing
2023-12-01
Not yet open
Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement
NCT06131489Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus, Bowel Resection
Beijing Friendship Hospital
Observational
20
Beijing
2023-12-01
By invitation
Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)
NCT06643858Healthy, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Neurodegenerative Diseases
Beijing Tiantan Hospital
Observational
10,000
Beijing
2023-12-01
Recruiting
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
NCT06799637Advanced Solid Tumors, Pancreatic Carcinoma, Ovarian Cancer, Cervical Cancers
Evopoint Biosciences Inc.
Phase 1/2
350
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Guiyang, Baoding, Harbin
2023-12-01
Recruiting
To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.
NCT05925452Active Systemic Juvenile Idiopathic Arthritis
Changchun GeneScience Pharmaceutical Co., Ltd.
Not applicable
290
Beijing, Chongqing, Changsha, Nanjing, Suzhou, Shanghai, Xiโ€™an, Chengdu
2023-12-01
Not yet open
A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.
NCT06142617Non Small Cell Lung Cancer, Immune Checkpoint Inhibitor, EGFR Exon 21 Mutation
Peking Union Medical College Hospital
Phase 2
37
Beijing
2023-12-01
Recruiting
An Exploratory Study of Focal Pulse Ablation System in the Treatment of Atrial Arrhythmia
NCT06157437Typical Atrial Flutter, Atrial Fibrillation (AF)
Hangzhou Dinova EP Technology Co., Ltd
Not applicable
10
Beijing
2023-12-01
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
BeOne Medicines
Phase 1
433
Beijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shenyang, Shanghai
2023-12-01
Recruiting
Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node (S-M-O-O-T-H)
NCT06146946Rectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
1,384
Beijing, Shanghai, Chengdu
2023-12-01
Active, closed
EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy
NCT06194825Transthyretin Amyloid Cardiomyopathy
AstraZeneca
Phase 3
64
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Haโ€™erbin, Jinan
2023-12-01
Recruiting
Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC
NCT06170710Head and Neck Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
173
Beijing
2023-12-01
Recruiting
NV-001 in the Treatment of Advanced Solid Tumors
NCT06051760Malignant Neoplasm
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 1
20
Beijing
2023-12-01
Not yet open
Evaluate the Efficacy and Safety of Edoxaban on Prevention of Catheter-related Thrombosis (CRT) in Cancer Patients
NCT06149533Thrombosis, Venous, Cancer, Catheter Complications
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 3
366
Beijing
2023-11-30
Recruiting
Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
NCT06876688CNS Lymphoma
Ruijin Hospital
Phase 2
30
Beijing, Guangzhou, Henan, Shanghai, Wuhan
2023-11-30
Recruiting
Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)
NCT06347653Nodal T-follicular Helper Cell Lymphoma
Peking University
Phase 2
54
Beijing
2023-11-28
Active, closed
Chronic Kidney Disease Registry Platform Study
NCT06117852Chronic Kidney Diseases
AstraZeneca
Observational
5,000
Baotou, Beijing, Changsha, Changzhou, Chengdu, Chongqing, Dongguan, Guangzhou
2023-11-28
Recruiting
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT06155383Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd.
Phase 2
90
Beijing, Fuzhou, Kunming, Xiamen, Wuwei, Guangzhou, Harbin, Zhengzhou
2023-11-27
Recruiting
Human Dental Pulp Mesenchymal Stem Cells for the Treatment of Chronic Periodontitis Patients
NCT05924373Periodontitis
Peking University Third Hospital
Phase 2
204
Beijing
2023-11-27
Recruiting
NOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI
NCT05638867Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome
China National Center for Cardiovascular Diseases
Phase 4
3,944
Beijing
2023-11-25
By invitation
A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors
NCT06115642Advanced/Metastatic Malignant Solid Tumors
Shanghai Henlius Biotech
Phase 1
367
Beijing, Changsha
2023-11-24
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
AstraZeneca
Phase 3
625
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2023-11-23
Active, closed
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491Metastatic Castration-Sensitive Prostate Cancer
AstraZeneca
Phase 3
1,898
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Guilin
2023-11-21
Active, closed
Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor
NCT06057571Cholangiocarcinoma Metastatic
TransThera Sciences (Nanjing), Inc.
Phase 2
50
Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou
2023-11-17
Recruiting
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
NCT06008054Esophageal Cancer, Gastric Cancer, Colorectal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
376
Beijing
2023-11-16
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356Non-Small Cell Lung Cancer (NSCLC)
Amgen
Phase 3
750
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2023-11-16
Recruiting
A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis ๏ผˆEGPA๏ผ‰
NCT05979051Eosinophilic Granulomatosis With Polyangiitis
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2/3
166
Beijing, Hangzhou
2023-11-16
Recruiting
A Study of the Efficacy and Safety of Antiwei Granules in the Treatment of Common Cold
NCT06697886Common Cold
Tasly Pharmaceutical Group Co., Ltd
Phase 3
480
Beijing, Changsha, Chengdu, Haerbin, Huizhou, Kaifeng, Luoyang, Luzhou
2023-11-16
Recruiting
Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
NCT06359847Differentiated Thyroid Carcinoma
Beijing Scitech-Mq Pharmaceuticals Limited
Phase 2
60
Beijing
2023-11-15
Active, closed
A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs
NCT06020144Rheumatoid Arthritis
Hangzhou Highlightll Pharmaceutical Co., Ltd
Phase 3
459
Beijing
2023-11-15
Recruiting
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06095583Limited-stage Small Cell Lung Cancer (LS-SCLC)
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
756
Harbin, Changsha, Nanchang, Shenyang, Jinan, Anyang, Beijing, Changchun
2023-11-15
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
AstraZeneca
Phase 3
1,902
Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin
2023-11-14
Not yet open
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
NCT05990127Locally Advanced or Metastatic NSCLC
Akeso
Phase 3
642
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Zhangzhou, Lanzhou
2023-11-14
Recruiting
A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behรงet's Disease
NCT06145893Behรงet's Disease
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 3
162
Beijing, Xiamen, Guangzhou, Shenzhen, Guilin, Shijiazhuang, Xinxiang, Nanchang
2023-11-13
Recruiting
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
NCT05319353Cytomegalovirus (CMV)
Takeda
Phase 3
80
Beijing, Guangzhou, Shenzhen, Shanghai, Tianjin
2023-11-13
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT06074588Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Phase 3
556
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2023-11-12
Active, closed
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821CLL
BeOne Medicines
Phase 3
652
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Jieyang, Nanning, Nanyang
2023-11-11
Active, closed
Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
NCT06189183Thymus Neoplasms
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
50
Beijing
2023-11-11
Recruiting
Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer
NCT06120387Locally Advanced, Urothelial Carcinoma Ureter
Xuesong Li
Observational
90
Beijing
2023-11-10
Not yet open
Safety and Efficacy Study of Implantable Neuromodulation for Poststroke Hemiplegia
NCT06121947Stroke Sequelae, Deep Brain Stimulation, Vagus Nerve Stimulation, Motor Recovery
Chinese PLA General Hospital
Not applicable
98
Beijing
2023-11-10
Active, closed
Single-Cell Sequence Technology Used to Reveal Heterogeneity of Secondary Hyperparathyroidism
NCT06130683Secondary Hyperparathyroidism
China-Japan Friendship Hospital
Observational
12
Beijing
2023-11-10
Active, closed
Evaluate the Safety, Tolerability of BAT6026
NCT06094179Dermatitis, Atopic
Bio-Thera Solutions
Phase 1/2
33
Beijing
2023-11-09
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
AstraZeneca
Phase 3
863
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Kunming, Lanzhou
2023-11-09
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Beijing, Guangzhou, Hangzhou, Lanzhou, Shanghai, Tianjin
2023-11-08
Active, closed
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
Pfizer
Phase 3
1,571
Beijing, Fuzhou, Guangzhou, Guiyang, Shijiazhuang, Nanyang, Wuhan, Changsha
2023-11-08
Active, closed
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT06122779Heart Failure
Bristol-Myers Squibb
Phase 2
227
Beijing, Guangzhou, Luoyang, Changsha, Hangzhou
2023-11-07
Recruiting
Personalized KSX01-TCRT in Patients With Advanced Solid Tumors
NCT06150365Refractory Solid Tumors, Relapsed Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase EARLY_PHASE1
12
Beijing
2023-11-07
Active, closed
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835Chronic Kidney Disease With High Proteinuria
AstraZeneca
Phase 3
1,835
Baotou, Beijing, Changsha, Chengdu, Chongqing, Deyang, Foshan, Guangzhou
2023-11-07
Recruiting
A Study of ST-1898 for Unresectable or Metastatic Melanoma
NCT06359860Unresectable or Metastatic Melanoma
Beijing Scitech-Mq Pharmaceuticals Limited
Phase 1/2
64
Beijing
2023-11-07
Recruiting
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies
NCT05990803Cervical Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
130
Beijing
2023-11-06
Recruiting
A Study to Test Tetrandrine Tablets for Connective Tissue Disease-Related Lung Disease
NCT07319598Interstitial Lung Disease (ILD), Connective Tissue Disease-associated Interstitial Lung Disease
Peking University Third Hospital
Phase 4
100
Beijing
2023-11-02
Recruiting
Disease Characteristics of IR-CAD: a Case-control Study
NCT06007248Coronary Artery Disease, Coronary Artery Stenosis, Coronary Artery Restenosis, Coronary Artery Disease Progression
Peking Union Medical College Hospital
Observational
30
Beijing
2023-11-02
Recruiting
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
NCT06008106Melanoma
Shanghai Kechow Pharma, Inc.
Phase 3
165
Beijing
2023-11-02
Recruiting
First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma
NCT06070740Gastrointestinal Neuroendocrine Carcinoma
Peking Union Medical College Hospital
Phase 2
22
Beijing
2023-11-01
Recruiting
Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab
NCT06141265Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Peking University Cancer Hospital & Institute
Phase 2
116
Beijing
2023-11-01
Active, closed
Distinguishing Retroperitoneal Fibrosis and Sarcoma from Other Retroperitoneal Diseases Via Radiomics
NCT06741423Retroperitoneal Sarcoma, Retroperitoneal Fibrosis
Heidelberg University
Observational
600
Beijing
2023-11-01
Recruiting
A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
NCT06066203Non-hodgkin's Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
40
Beijing
2023-11-01
Recruiting
Multi-center Study on Comprehensive Diagnosis and Treatment of Lower Limb Bone Defect Based on Three-dimensional Printing Technology
NCT06269354Bone Defects
Peking University Third Hospital
Observational
120
Beijing
2023-11-01
Recruiting
Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer
NCT06154538Locally Advanced Colorectal Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
170
Beijing, Guangzhou, Jinan
2023-11-01
Not yet open
Radial Artery Versus No-touch Saphenous Vein
NCT06014047Coronary Artery Disease
China National Center for Cardiovascular Diseases
Not applicable
774
Beijing
2023-11-01
Recruiting
Study of Adrenocorticotropic Hormone on Children With Frequent Relapse or Steroid-dependent Nephrotic Syndrome: a Prospective, Multicenter, Randomized๏ผŒOpen-label Clinical Trial.
NCT06079788Nephrotic Syndrome in Children
Mao Jianhua
Phase 3
140
Wuhan, Nanjing, Kunming, Hangzhou, Ningbo, Wenzhou, Beijing, Shanghai
2023-11-01
Active, closed
Efficacy and Safety of TTM in Adults With ECPR.
NCT06608095Cardiac Arrest
Peking University Third Hospital
Not applicable
146
Beijing
2023-11-01
Recruiting
Aneurysmal Subarachnoid Hemorrhage Multi-Omics Research Program
NCT07270419Aneurysmal Subarachnoid Hemorrhage
Xiaolin Chen, MD
Observational
2,000
Beijing
2023-11-01
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626Metastatic Breast Cancer
LeonaBio
Phase 3
600
Anhui, Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqicun
2023-10-31
Recruiting
App and Body Fat Scale in the Management of Overweight Patients
NCT05866107Schizophrenia, Bipolar Disorder, Metabolic Syndrome, Overweight and Obesity
Capital Medical University
Not applicable
204
Beijing
2023-10-31
Active, closed
Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus
NCT05749874PreDiabetes, Abdominal Obesity, Hypertension, Dyslipidemias
China National Center for Cardiovascular Diseases
Phase 4
2,024
Beijing
2023-10-31
Recruiting
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
NCT06081959Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
376
Beijing
2023-10-31
Recruiting
Anti-inflammatory Therapy for Recurrent In-stent Restenosis
NCT06090890In-stent Restenosis
Fu Wai Hospital, Beijing, China
Phase 4
252
Beijing
2023-10-30
Recruiting
Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients
NCT06098560Colorectal Cancer
Geneplus-Beijing Co. Ltd.
Observational
60
Beijing, Shanghai
2023-10-30
Recruiting
Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
NCT06190067Relapsed Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Navy General Hospital, Beijing
Phase 2
40
Beijing
2023-10-30
Not yet open
A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke
NCT06077305Cerebral Small Vessel Diseases, Ischemic Stroke
Beijing Tiantan Hospital
Observational
20,000
Beijing
2023-10-30
Recruiting
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
NCT06008288KRAS P.G12C, Pancreatic Cancer, Solid Tumor
Allist Pharmaceuticals, Inc.
Phase 2
88
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-10-27
Rows per page Showing 3901–4000 of 5484
Previous 38 39 40 41 42 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=40

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.